REG - Medpal AI PLC - Secondary Listing on Frankfurt Exchange

Medpal AIAnnouncement

Tue 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260203:nRSC5601Ra&default-theme=true

RNS Number : 5601R  Medpal AI PLC  03 February 2026

MedPal AI plc

("MedPal AI" or the "Company")

Secondary Listing on the Frankfurt Stock Exchange

MedPal AI (AIM: MPAL
(https://www.londonstockexchange.com/stock/MPAL/medpal-ai-plc/company-page) ,
FRA: Z1N
(https://live.deutsche-boerse.com/equity/medpal-ai-plc-ls-0002?mic=XFRA) ), a
UK-based digital health and artificial intelligence ("AI") company focused on
health and wellness management, is pleased to announce that the Company's
ordinary shares have been admitted to trading on the Open Market (Freiverkehr)
of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse, "FRA"),
operated by Deutsche Börse AG, with trading under the ticker Z1N commencing
today.

Listing Details

 Exchange                    Frankfurt Stock Exchange (Frankfurter Wertpapierbörse)
 Market Segment              Open Market (Freiverkehr)
 Trading Symbol              Z1N
 ISIN                        GB00BTRC7N37
 WKN (German Securities ID)  A41GSJ

 

The Frankfurt listing is a secondary listing and sits alongside the Company's
primary quotation on the AIM market of the London Stock Exchange. Trading in
the Company's shares on the AIM market will continue as previously and the
Company will continue to make all regulatory disclosures via RNS.

Strategic Rationale

Germany represents one of Europe's largest and most dynamic private investor
markets. According to figures published by Deutsches Aktieninstitut, the
number of retail investors in Germany reached a new record high of 14.1
million in 2025, driven in particular by younger investors up to the age of 39
who now represent the largest investor cohort.

This growing pool of engaged private investors, combined with the Frankfurt
Stock Exchange's position as the third largest exchange in Europe by market
capitalisation and its role as a trading venue primarily serving private
investors with access to over one million securities, provides the Company
with a significant opportunity to broaden its shareholder base and increase
trading liquidity.

The rise of low-cost European neo-broker platforms has further democratised
access to dual-listed securities on the German exchanges, enabling retail
investors to trade at minimal cost. The Board believes that a dual listing in
Frankfurt positions MedPal AI to capitalise on these favourable structural
trends and to build visibility among a new and substantial audience of
European retail investors.

The Frankfurt listing also coincides with the Company's planned expansion into
the German market. MedPal AI has launched a German-language version of its
AI-powered wellness application to coincide with the listing, marking the
first step in the Company's European growth strategy. Over the next six
months, the Company intends to extend additional MedPal services into Germany,
leveraging the country's rapidly growing digital health market which is
expected to expand at a compound annual growth rate in excess of 20% through
to 2030.

In support of the Frankfurt listing, MedPal AI will be presenting at an
investor event in Germany in mid-March 2026, providing an opportunity to
engage directly with the German investment community and to introduce the
Company's integrated AI healthcare platform to a broader European audience.

Company page on the Deutsche Börse:
https://live.deutsche-boerse.com/equity/medpal-ai-plc-ls-0002?mic=XFRA
(https://live.deutsche-boerse.com/equity/medpal-ai-plc-ls-0002?mic=XFRA)

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"We are delighted to announce our secondary listing on the Frankfurt Stock
Exchange, which represents an important milestone in MedPal AI's growth as a
European digital health company. Germany is home to one of the continent's
most active and expanding retail investor communities, and a dual listing
provides us with access to this significant pool of capital and visibility.

"The timing of this listing is deliberate. By simultaneously launching a
German-language version of our AI wellness app and committing to a broader
rollout of MedPal services across Germany over the coming months, we are not
simply listing our shares in a new market - we are entering the market as a
business. Our presentation to German investors in March will provide an
opportunity to demonstrate the strength of our integrated healthcare platform
and our ambitions for the European market."

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer                   Via Square1 Consulting
 Cairn Financial Advisers LLP                              +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner
 Clear Capital Markets Limited                             +44 (0) 20 3869 6080

 Bob Roberts
 Square1 Consulting                                        +44 (0) 20 7929 5599

 David Bick                                                +44 (0) 7831 381201

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKNBDQBKDCBK



            Copyright 2019 Regulatory News Service, all rights reserved